

Neurocysticercosis: A Health Burden in Nepal

Basant Pant,^{*1} Bishnu Joshi ^{*1,2}, Pravesh Rajbhandari¹, Ram Prasad Aganja ² Rajani Malla², Krishna Das Manandhar², Lakshmaiah Sreerama^{3,4}

¹Annapurna Neurological Institute and Allied Science, Kathmandu, Nepal

²Central Department of Biotechnology, Tribhuvan University, Kirtipur, Nepal

³Department of Chemistry, St Cloud State University, St Cloud, MN 56301, USA

⁴Department of Chemistry and Earth Sciences, Qatar University, Doha, Qatar

ABSTRACT

Objective: This review paper is aimed at highlighting the burden of Neurocysticercosis in general and its impact in Nepal in particular as it relates to etiology, pathogenesis, current treatment practices, and recommendations to prevent this disease.

Methods: General peer review of literature related to Neurocysticercosis with a focus on the Nepalese context, and the incorporation clinical data and practices to substantiate our findings.

Findings: In patients burdened by this disease epileptic seizures are common. Computerized tomography scanning and magnetic resonance imaging techniques are most commonly used investigative tools for the diagnosis of NCC. Radio-imaging techniques combined with serological techniques such as enzyme-linked immunosorbent assay and/or enzyme-linked immunoelectrotransfer blot analysis are commonly used as confirmatory diagnostic tools for this disease. The most effective treatments for neurocysticercosis are tailored to individual patients that involve the use of antiepileptic drugs, analgesics, corticosteroids, and/or a combination of these. Anthelmintic drugs (albendazole) are used to treat multiple lesion neurocysticercosis.

Conclusion: It is a preventable disease, accordingly, the best way to minimize the burden of this disease in underdeveloped countries such as Nepal is via (i) education of the public about the disease, (ii) promoting safe pork production practices, (iii) providing running water supplies and

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

developing underground sewage systems, and (iv) improving personal hygiene and sanitation practices.

Key words: Neurocysticercosis, computerised tomography (CT-Scan), epilepsy

1. INTRODUCTION

Neurocysticercosis (NCC) is an infection of central nervous system by the larvae of tapeworm *Taenia solium* (*T. solium*). It is the oldest and most common helminthic infection that leads to acquired epilepsy worldwide[1]. Humans acquire taeniasis by eating raw or undercooked pork infected with cysticerci, the larval stage of *T. solium*. Transmission of cysticercosis occurs following environmental contamination with infective eggs released from the human tapeworm carrier. In developing countries, where sanitary infrastructures are often deficient, free-roaming swine acquire cysticercosis after eating human faeces containing eggs. In humans, the larval stage can also establish following accidental ingestion of eggs through eating fecal contaminated food. The disease is mostly localized to the regions where sanitation facilities such as running water supplies and underground sewage systems are lacking and hygiene (personal and otherwise) conditions are generally poor. The movement of people for better lives via immigration, migration and globalization processes has increased the spread of this disease to non-endemic regions of the world. NCC is the major health concern in the endemic areas such as Mexico, Africa, South-East Asia, Eastern Europe, and South America [2, 3], however the prevalence of the NCC is low in Israel, Middle-East, and most Muslim countries of Africa and Asia [4, 5]. World-wide, about 50 million people are estimated to be infected by *T. solium* and suffer from NCC and an estimated 50 thousand people die from this disease annually [6]. Further, the disease also affects unknown numbers of people from neurological burden in a productive age group [7]

2. PARASITIC LIFE CYCLE AND PATHOGENESIS

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

The life cycle of *T. solium*, Figure 1, includes the swine as an intermediary host where the tapeworm develops into the larval stage. The larval stage is transmitted to humans when insufficiently cooked infected pork meat is ingested. The adult *T. solium* can be 2-8 m in length, inhabits in the small intestine and has a life-span of up to 25 years. It attaches itself to the intestinal mucosa by its double row of hooks and four suckers in the rostellum. On a regular basis as the stool passes through the intestine, 5-6 gravid proglottids (collection of fully embryonated and infective tapeworm eggs) from the distal end of the worm are passed along with the feces. Each proglottid is known to contain thousands of eggs and they are very resistant to adverse environments. In regions where open defecation is practiced and swine farming is common, the wandering swine (intermediate host) consume human feces which includes feces that may contain *T. solium* proglottids. These proglottids are emulsified by the bile and subject to proteolysis by pancreatic enzymes. These processes loosen the coatings of the proglottids and the eggs, and thousands of the oncospheres (infective embryos) are thus liberated. These oncospheres cross the intestinal wall, enter the bloodstream, and are carried to muscle and other soft tissues including CNS. It takes about 60-70 days for the oncospheres develop into the cysticerci. The consumption of meat containing cysticerci results in taeniasis. It was previously incorrectly assumed that cysticercosis was acquired mainly through eating raw/improperly cooked pork, but it is now clear that any uncooked food that may be contaminated with *T. solium* eggs may also transmit (Figure 1) cysticerci. Thus, in endemic areas, the disease is likely to burden all people that may be exposed to *T. solium* proglottid contaminated food[8, 9]. The cysts have predilection to lodge in areas where the flow of blood is high and the major parts they reside are in brain, eye and muscles. The high glycogen or glucose content of these tissues (brain, muscle) may be responsible for such a tropism exhibited by cysticerci [10]. When they lodge in muscle the cysts will remain asymptomatic, whereas in the brain they will cause neurocysticercosis [11]. Cysts are also known to reside in the heart, spinal cord and skin; however such cases are very rare.

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

81

82 3. EPIDEMIOLOGY OF CYSTICERCOSIS AND NEUROCYSTICERCOSIS IN NEPAL

83 Literature dealing with cysticercosis (epidemiological or otherwise) in Nepal is limited. Efforts are
84 made herein to summarize all available literature as well as add to that knowledge by including
85 our own data and experiences dealing with this disease in Nepal. While occurrence of
86 cysticercosis is considered as a “biological marker” of the social and economic development of a
87 community[12], it is difficult to quantify the burden of neurocysticercosis in that community study.
88 This is because of (i) its polymorphic presentation, i.e., some patients suffer only one or two
89 episodes of seizures in the entire course of their illness while others exhibit recurrent seizures, (ii)
90 the infection remains in latent phase throughout the life of some patients[13] and (iii)
91 disappearance of some of the lesions in certain patients. Apart from these clinical features, social
92 stigma associated with epilepsy forces the patients and/or their families to avoid seeking medical
93 assistance. Additionally, some patients with other disorders, e.g., patients with syncope, migraine
94 with aura, somatoform disorders, transient ischemic attack, focal stroke, etc., may present an
95 acute event of seizure-like symptoms that may be interpreted or misdiagnosed as being
96 neurocysticercosis. For example, in a recent study Devleesschauwer and associates[14] have
97 concluded that socioeconomic status and poor personal hygiene are the major cause for the
98 transmission of the zoonotic pork tapeworms *T. solium* and *T. asiatica*. Similarly the prevalence of
99 taeniasis was found to be high among the *Dum* Community. This suggests that high rate of
100 taeniasis in the certain groups might be of particular importance for maintaining the life cycle of
101 the zoonotic swine tapeworms. This study also identified the carriers of tapeworm and determined
102 the species to be *T. asiatica* in the endemic region of Southeast Nepal. NCC has been a
103 common cause of epilepsy among the Nepalese soldiers[15]. Prevalence of NCC in Nepal ranges
104 from the 0.002 to 0.1%[16], on the other hand, recent studies in the endemic region [17], the
105 porcine cysticercosis seems to be rather high, e.g., the prevalence was 32.5 % in 419 individual
106 porcine samples tested by lingual palpation technique. Although still high, the prevalence of

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

porcine cysticercosis among the 204 porcine sera samples tested was 23.5% when the testing technique used was ELISA [17]. Further, in this study, the taeniasis reporting ranged from 10-50% [17]. In 2012, the neurology service unit of Tribhuvan University teaching hospital (Kathmandu Nepal), reported 66 (36 male and 30 female) cases of NCC[18]. Among these 77.2% of the patients presented seizures. Computerized Tomography Scan (CT- scan) showed single ring-enhancing lesions in 42 cases (63.6%) and multiple ring enhancing lesions in the remaining 24 cases (36.3%). Most lesions were seen in parietal region (63.6%), followed by frontal (13%), temporal (9%) and occipital (9%) regions. A similar study conducted in a Kathmandu Model Hospital (n=724 patients), 61% of patients exhibited seizures and 72% of them were focal seizures due to NCC. The mean age of patients in the study was 13 years, and both sexes were found equally affected. Among these patients, 71% showed stage II lesions (dying cyst with or without edema, Table 1 and the remaining patients had stage III lesions (calcified). Overall, 61% of lesions were solitary and 31% were multiple lesions (Pant, 2006). In western region of Nepal, Basu and associates in 2007 [19] have observed that the mean age at which NCC occurs was at 10.8 years (range 11 months - 15 years, most commonly affected age group 10 - 12 years; 8.9% patients were below 2 years of age). In yet another study [20] they examined 93 patients (age range: 2-14 years; 10.3% patients <6 years of age) presenting new onset seizures from Lumbini region; 73% of the patients had NCC. These observations were confirmed by radio imaging techniques. This was further confirmed Shrestha in 2008 [21]. It is important to note that most of the epidemiological studies conducted in Nepal were at Tertiary Hospitals, they are retrospective studies and the diagnosis was based on the radio imaging techniques.

Cysticercosis and NCC may also be diagnosed using immunological techniques. Immunological techniques are directed towards detecting specific proteins secreted by *T. solium* and/or specific antibodies against *T. solium* cysticerci in serum. In this regard, Maharjan and associates in 2002 applied an enzyme-linked immunoelectrotransfer blot (EITB) analysis technique to study cysticercosis in porcine using blood samples (n=201). The study showed 24% prevalence of

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

cysticercosis in the tested porcine samples , 6% of them were found to be old infections or exposures. In our own study, EITB was utilized to screen for NCC using blood samples collected from patients (n= 60) that underwent CT-scanning. Most of the patients with multiple cysts showed a positive EITB test. On the other hand, among the patients with single cyst, the EITB test was positive only in a few patients. The EITB test failed to show reactive bands in the old calcified cysts. Out of 60 samples collected from patients with NCC, as suggested by CT-scan/Magnetic Resonance Imaging (MRI), EITB test was found to be positive in 18 cases. The lower percentage (30 %) of EITB positive in the samples analyzed may be due to single cyst granuloma (SCG) (Figure 2).

4. CLINICAL CHARACTERISATION OF NEUROCYSTICERCOSIS

NCC is a chronic progressive disease and the severity of the disease depends on (i) number of cysts and their location in the brain, (ii) stage of infection and intensity of host inflammatory response in the brain, and (iii) the parasite genotype[1]. In South Asian communities, including Nepal, the clinical presentation of the disease is generally considered to be solitary cysticercus granuloma as suggested by CT scans (a single ring-shaped lesion). However in some cases multiple cysts have been observed (Figure 3). In these communities, the optic cysticercosis has been rarely observed (Figure 4). Surface/cortical lesions are notorious for producing lifelong seizures due to calcification and subsequent scarring (Figure 5). These enhancing lesions are usually less than 20 mm in diameter and are surrounded by a varying amount of perilesional vasogenic edema. The presence of a single cyst in majority of Nepalese and/or Indian populations may be due to Toll-Like Receptor-4 (TLR4) with D299G and T399I polymorphisms. These polymorphisms are presumed to be associated with the development of symptomatic NCC via the modulation of Th1/Th2 axis[22, 23]. Similarly, depending on the location of the cysts, various neurological symptoms can occur, however they are uncommon (4-6%) in children from this region. Cysts in the midbrain are known to cause ptosis. In patients with multiple cysts in the midbrain, young children and adolescents, especially females, exhibit acute encephalitic

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

presentation characterized by cerebral edema, and severe acute raised intracranial pressure. The most common symptom of NCC is seizures (70%-80% of the patients). These seizures are more frequent between 2nd and 5th decade of life and they are, most frequently, generalized tonic clonic seizures (GTCS) [24]. In addition to NCC, the seizures may also be caused by other factors, e.g., trauma, presence of tumor mass. Additional factors for seizures include congenital factors, infections, etc. (Figure 6). It appears that the seizures are especially common when the cysts are associated with parenchymal tissues. In a retrospective study of 250 patients visiting our hospital (Annapurna Neurological Institute and Allied Science, Kathmandu, Nepal) presenting seizures, we have found that 47.1 % of the patients had GTCS. This was followed by focal seizures secondary generalized (FSSG) in 30%, complex partial seizure (CPS) in 3.6%, atonic seizure (AS) in 2.9%, simple partial seizure (SPS) in 2.1% and drop attack (DA) in 0.7% of the patients (Figure 7).

The asymptomatic to sudden onset of symptoms of NCC is due to the status of the cyst as well as its location. Neurological imaging techniques reveal that these cysts exist in various stages of development and/or deformity, e.g., i) vesicular stage - the cyst contains live larva, ii) colloidal stage - the cyst begins to degenerate, iii) granular nodular stage - the cyst membrane thickens and calcification begins and iv) calcified stage – the cyst is fully calcified and necrotized. In patients with vesicular or colloidal stage cysts, the live larvae may elicit host immune response, and the degenerations and/or bursting of cyst results in edema which ultimately leads to seizures.

Given the above, a patient may present a focal seizure (FS), FSSG, GTCS or intractable seizures. Focal neurological deficit can also occur depending on the location of lesions, e.g., diplopia in brainstem. Clinical features of raised intracranial pressure (ICP) such as headache and vomiting in cases with obstructive hydrocephalous, generalized edema in patients with multiple cysts of different stages. Blindness or visual deficit in patients with NCC can be due to intra ocular lesions (lesions along the pathway of vision). The lesions can also lead to different

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

cognitive dysfunctions. The clinical radiological correlations of these conditions are described in in Table 1.

4.1 RADIOLOGICAL DIAGNOSIS OF NEUROCYSTICERCOSIS

The radiological diagnosis of NCC is done through imaging techniques such as CT-scanning and/or MRI. The characteristics of neuroimaging include the appearance of scolex as hyper intense nodules (hole-with-dot) as well as puncture calcification. CT is the best radiological method for the detection of intra-parenchymal calcifications, whereas MRI method is more suitable to resolve the differential diagnosis of NCC as it provides objective based evidences on i) the number and the topography of the lesions, ii) its stage of the involution, and iii) the degree of the inflammation. MRI is more effective in detecting extra-parenchymal NCC. One shortcoming of this technique is that it fails to detect small calcifications. In some of the cases, neither CT-scan nor MRI can detect the parasites when they are located at the subarachnoid basal cisterns[25]. Further, CT-scans of NCC and tuberculomas, pyogenic brain abscesses, mycotic granulomas, and primary and/or metastatic brain tumors often appear identical [26]. To differentiate NCC from tuberculoma and other factors such as cyst wall thickness, spontaneous disappearance of the lesion and the mid-line shift are also taken into consideration. Therefore, a more reliable techniques and/or additional diagnostic techniques for the detection of NCC are essential. One such diagnostic tool could be serological blood tests (described below). Although, CT scan and/or MRI techniques have their own technical limitations, the major limitation of the imaging techniques from the view of a patient are the accessibility and the cost associated with diagnosis for the endemic populations at risk. In poor regions of the developing world, including rural Nepal, this is not only true but a major challenge. In these regions, healthcare systems are poorly developed and the patients not only have to travel to cities for diagnosis but also cannot afford the cost associated with these tests.

4.2 IMMUNODIAGNOSIS OF NEUROCYSTICERCOSIS

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

Immunodiagnosis of NCC involves the detection of proteins (antigens; Ag) secreted by *T. solium* and/or detection of circulating antibodies (Ab) against *T. solium* proteins. In fact, this would be a low cost diagnostic tool that can be effectively used for screening in the endemic areas[27]. For the detection of antibodies, either an ELISA (enzyme-linked immuno-sorbent assay) and/or EITB assays are the most commonly employed. The antibodies against *T. solium* proteins can be detected in the serum, saliva and even in the tears of patients with ophthalmic cysticercosis. Other techniques used to detect the antibodies against *T. solium* include radioimmuno assays (RIA), hemagglutination tests, complement fixation test and dipstick assay. The serological tests are targeted to detect the presence of antigens by ELISA is a promising technique for monitoring the success of NCC treatment because of an excellent correlation between the presence of circulating antigen and viable brain cysts. Similarly, high seropositivity rates for cysticercosis are significantly associated with tapeworm carrier clusters and the seropositive persons are significantly clustered within households, particularly, in households in which a member reported a history of having passed tapeworm proglottids, as well as with individuals with a clinical history of seizures ([28]). Though ELISA is widely used to detect NCC, its sensitivity is poor. The sensitivity and specificity of ELISA are respectively 50% and 70% when serum samples are used for testing [27, 29, 30]. On the other hand, the testing sensitivity and specificity are, respectively 87% and 95% when CSF samples used for testing [31]. Recently, the study carried by Carod et.al [32] evaluated the 5 enzyme immune assay for detecting human antibodies against *Taenia solium* in serum for the diagnosis of NCC, the all the test showed sensitivity under 72% and specificity above 60 %. Recently, Two monoclonal antibody based tests (B158/B60 Ag-ELISA and HP10 Ag-ELISA) have been validated and are used routinely for the detection of parasite antigens [33, 34]. The measurement of circulating antigen levels allows differentiation of NCC cases with viable parasites, with antigen levels correlating to the numbers and size of the lesions. For instance, antigen levels were 10 times higher in extraparenchymal NCC (particularly subarachnoid NCC) than in intraparenchymal NCC, therefore high antigen levels should lead one

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

to suspect the presence of extraparenchymal NCC. In addition, there have been efforts to try to correlate the result in an immunodiagnostic test with the location and state of the cysticerci in the brain. An example is the detection of the antigen HP10 in CSF, which correlates with the location of the cysticerci in the brain: when located in the subarachnoidal space or the ventricles, HP10 could be detected, but when located in the parenchyma HP10 could not be detected; and when cysts were damaged, HP10 levels are reduced significantly [34, 35]. Also high antigen levels in CSF suggest the presence of subarachnoid NCC. The major demerit of the ELISA technique is false positive tests especially when the patients are infected with *Hymenolepis nana* and *Echinococcus granulosus*[36]. A comparative study of ELISA and dot-blot assay using blood samples from children with multiple brain lesions was found to be both sensitive and equally effective in diagnosis of NCC[37]. The antigen detecting ELISA tests have better sensitivity with the use of CSF specimens as compared with serum samples; however, CSF collection requires lumbar puncture[34]. The lumbar puncture involves additional risks, the procedure is invasive and the procedure has to be performed by a trained medical professional. Given the above, this technique is not routinely practiced. It has been reported that a *T. solium* cyst fluid based lymphocyte transformation test (LTT) as a diagnostic tool for NCC is most sensitive (93.7%) and specific (96.2%). [38]. Even for the single cyst infection the sensitivity of this test was 87.5%. This test has future potential provided the test can be made more user friendly based on spectrophotometry.

5. ENZYME LINKED IMMUNOELECTROTRANSFER BLOT (EITB) ASSAY

To date, EITB is the most specific and sensitive test developed for the diagnosis of NCC by the Centers for Disease Control, Atlanta, USA. This test is considered a gold standard in serological diagnostic tests for NCC. The test detects antibodies against seven cysticerci glycoproteins.

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

Immunoreaction with any one of the seven specific proteins is regarded as the positive test for cysticercosis (Figure 8). This assay has been used worldwide for nearly 15 years both in serological screening to determine prevalence of cysticercosis and for the diagnosis of individuals with NCC [39, 40]. It is the only assay recognized by the WHO and the Pan American Health Organization for the serological diagnosis of cysticercosis[41]. Initially, the test was considered to be 100% specific and 98% sensitive [42], however, Wilson and associates in 1991 [43] demonstrated that EITB to be only 28 % sensitive when applied to serum samples collected from patients with single cysts. In general, the serum EITB is more sensitive than that of CSF EITB. An EITB is less likely to give a positive test for cysticercosis in patients with calcified lesions as compared to those with active or transitional cysts. Further, the EITB tests may become negative after the cyst dies[44]. A demerit of the EITB test for diagnosis of NCC is that it can be positive in patients with taeniasis. A positive EITB test is of less diagnostic value in patients from areas where cysticercosis is endemic. Conversely, a negative EITB test does not exclude a diagnosis of NCC in patients with a single cyst or in those with brain calcifications as the only evidence of the disease. Another limitation of antibody-based tests is that the presence of antibodies may indicate only previous exposure to or infection with the parasite, and not necessarily a viable infection [45, 46]. In fact, in the scenario above, two-thirds of serologically positive individuals have no identifiable lesions on CT scans[47]. Thus, the presence of antibodies does not constitute direct evidence of a living parasite within the host[48]. For example, in Ecuador, 86% of the patients with active lesions, 67% of the patients with transitional lesions and 41% of the patients with inactive lesions were found to be positive by EITB assay with as overall sensitivity of 53.6%. In a more recently published report from the India[49], only, 26% of the patients with CT scan diagnosis of NCC were found to be positive by EITB tests. To overcome these limitations, attempts have been made to develop antigen-based assays, since detection of antigens is an indicator of the presence of live and active cysticerci[50].

6. TREATMENT

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

The treatment of NCC should be individualized and it should be based on the disease pathogenesis in any given patient. In this regard, the Del Brutto [51] diagnostic criteria for NCC, Table 2, is recommended. This uses a number of factors to tailor the therapy, e.g., the location of the cysts, symptoms, viability of the cysts and the degree of host response. In practice, the therapy for NCC is mostly directed to alleviate symptoms associated with NCC and it includes administration of antiepileptic drugs for seizures. In patients having high ICP, mannitol and oral glycerol is generally administered to reduce ICP. Corticosteroids are commonly administered to patients to reduce inflammation and edema. Albendazole in combination with either dexamethasone or prednisolone are considered for the adults and children with NCC to dissolve the cysts and reduce the incidence of seizures [52]. Improvements in treatment strategies should include the determination of the location of the cyst (e.g., intraventricular, subarachnoid or intraocular etc.) as well as use of antihelminthes drugs when the NCC patients also have HIV infection [52].

6.1 ANTICYSTICERCAL DRUGS

Praziquantel, an isoquinolone, and albendazole, an imidazole, are the most commonly used anticysticercal drugs, especially in the treatment of intracranial cysticercosis. They are very effective in the elimination of cysticerci in the brain parenchyma and/or, at least, markedly reduce number of cysts in other locations [53]. In several comparative trials, albendazole appeared slightly more effective than praziquantel for the treatment of parenchymal NCC. Albendazole has also been found to be effective against giant parenchymal, subarachnoidal, intraventricular and even spinal forms of cysticercosis, [54]. In a double blind placebo controlled trial, 63 children with a single lesion NCC administered with albendazole (15 mg/kg/day) for a 4 week period resulted in marked reduction in the onset of seizures and faster disappearance of lesions (41% within a month as compared to 16,2% in placebo patients [43]. This study also found that an 8-day

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

course of albendazole is as effective as 15 or 30 day course of albendazole treatment [43]. In a randomized controlled trial from Ecuador, neither praziquantal nor albendazole was found to be effective against viable cysts [55]. Similarly, in a recent randomized trail from the Ecuador (n=175), it was found that only 31% patients receiving albendazole were free of any active cysticerci as compared to 7% among the placebo group [56]. Although this variation is somewhat contradictory, it is possible that variation could be due to polymorphisms associated with faster rate drug metabolism (detoxification) in the host or insensitivity of cysticerci to the drugs.

The side effects of cysticercosis treatment with albendazole or praziquantel include headache, nausea, vomiting and seizures. These effects are generally transient. The transient nature of the side effects associated with albendazole or praziquantel treatment seem to due to the host's inflammatory reaction to dying parasites. Corticosteroids ameliorate most of the side effects listed above. Given the above, the authors' routinely co-administer corticosteroids and anticysticercal therapies to their own patients in Nepal as well as recommend these practices to their colleagues that treat NCC patients in Nepal [[57]. Fatalities associated with the parasitic treatments are rare (1-4%) and occur primarily in patients hydrocephalous, increased intracranial pressure and heavy cyst burden[58]. In patients with seizures, various antiepileptics, e.g., carbamazepine, phenytoin, phenobarbital and valproate have been used with roughly equal efficacy. The choice of drug, dose and duration of administration of antiepileptic would vary according to the clinical profile of the patients.

6.2 SURGERY

Surgical intervention (Figure 9) is required in some cases particularly in intra-ventricular and subarachnoid NCC. A ventriculo peritoneal shunt is needed for hydrocephalous; simultaneous use of steroids and albendazole and recurrent courses of steroids reduce the risk of frequent obstructions and shunt revisions. Endoscopic removal of cysts is the least invasive procedure and

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

is therefore the procedure of choice [59][60]. In some cases, excision of giant cysts that fail to respond to medical therapy may be required.

7. PROGNOSIS

The treatments described above have excellent prognosis in case of patients with single lesions. In these cases, the seizures are usually well controlled with the first line of antiepileptic drugs, and in 60% of the cases the cysts disappear. Some patients do require prolonged antiepileptic therapy, especially when parenchymal NCC have been calcified [61]. The recurrence of the seizures is common when the multiple cysts become calcified. Cysticercus encephalitis and extra-parenchymal NCC have the guarded prognosis.

8. PREVENTION STRATEGY

As per reported statistics and our own observations, most of the patients suffering from NCC come from the weaker economic sections of the society. In general they reside in villages with very poor or no sanitation systems in place. Such patients, in general, have no access to CT scan, MRI imaging facilities and/or reliable serological tests for the diagnosis of cysticercosis. These diagnostic tools are essential for the detection of the cysticerci in the brain and for the confirmation of the diagnosis. Given the above, prevention of NCC should be the priority for health systems. This is especially true in countries such as Nepal. This should begin with prevention of cysticercosis. In this regard, education about health and hygiene and improvements in sanitary practices are very critical. This must include (i) establishing modern slaughterhouses and following hygienic practices in these slaughterhouses while processing pork, and (ii) mandatory requirement of antemortem and postmortem examination of swine for cysticercosis are critical. Other practices that could be considered as risk factors such as (i) deliberate use of human feces as pig feed, (ii) connecting pigpens to human latrines, (iii)

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

indiscriminate defecation in the public areas, and (iv) use of sewage effluents, sludge, or night soil as fertilizer in vegetable crop fields should be avoided.[17] Intervention programs to break the life cycle of parasite, e.g., porcine vaccination, anticysticercal drug treatment for the pigs infected with *T. solium*, education about proper meat cooking practices before consumption, treatment of household members if they suffer from taeniasis, etc., helps in prevention of this neglected disease[62]. Vaccination against taeniasis is not immunologically or logistically feasible at present, because the occult nature of the infection makes tapeworm carriers difficult to detect, and the minor morbidity associated with intestinal infection also makes taeniasis a poor candidate for human vaccine development[63]. Vaccinations against porcine cysticercosis are in the research phase. In the field trials, the most effective vaccination so far has been recombinant *Taenia solium* protein TSOL 18 and TSOL45-1A. The use of TSOL vaccination together with oxfendazole was effective in stopping the transmission of *T. solium* by porcine [64].

9. CONCLUSION

NCC the leading cause of acquired epilepsy in the developing countries including Nepal. This is a preventable disease but it is widely neglected. The realization of disease burden (cost associated with antiseizure medication, long term neurological sequel), the group of investigators have proposed to make this disease an internationally reportable disease. Better understanding of the immune response of the parasite for vaccine and drug development, and an effective intervention program is needed for the eradication of the cysticercosis in near future.

ACKNOWLEDGEMENT

We are very much thankful to Dr. Patricia Wilkins, Center for Disease Control (CDC, USA) for Providing the EITB strips and guidance for conducting the research work. We are also thankful to Mr. Subodh Kant Singh, Ms. Mandira Dahal and Kumar Basnet for providing data to prepare this manuscript.

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

AUTHORS' CONTRIBUTIONS

This work was carried out in collaboration between all authors. Authors BJ and BP conducted the review. Author PRB provides CT- Image and write down their descriptive findings. Authors RPJ, KDM and RM draft the article. Author LS was involved in review of the highlighting the shortcomings in the article and in extensive editing to make article worth reading. All authors read and approved the final manuscript

CONSENT

Not applicable

COMPETING INTERESTS

Authors have declared that no competing interests exist

REFERENCES

1. Garcia HH, Del Brutto OH: Neurocysticercosis: updated concepts about an old disease. *The Lancet Neurology* 2005, 4(10):653-661.
2. Rajshekhar V, Joshi DD, Doanh NQ, Van De N, Xiaonong Z: Taenia solium taeniosis/cysticercosis in Asia: epidemiology, impact and issues. *Acta. Trop.* 2003, 87(1):53-60.
3. Bharucha N: Epidemiology of epilepsy in India. *Epilepsia* 2003, 44:9-11.
4. Schantz PM, Moore AC, Muñoz JL, Hartman BJ, Schaefer JA, Aron AM, Persaud D, Sarti E, Wilson M, Flisser A: Neurocysticercosis in an orthodox Jewish community in New York City. *New England Journal of Medicine* 1992, 327(10):692-695.
5. Ocana GS, Sablon JCO, Tamayo IO, Arena LA, Ocana LMS, Govender S: Neurocysticercosis in patients presenting with epilepsy at St Elizabeth's Hospital, Lusikisiki. *SAMJ: South African Medical Journal* 2009, 99(8):588-591.
6. Roman G, Sotelo J, Del Brutto O, Flisser A, Dumas M, Wadia N, Botero D, Cruz M, Garcia H, Bittencourt PRM: A proposal to declare neurocysticercosis an international reportable disease. *Bulletin of the world Health Organization* 2000, 78(3):399-406.
7. White Jr AC: Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. *Ann. Rev. Med.* 2000, 51(1):187-206.

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

- 421 8. Brown W, Voge M: Cysticercosis. A modern day plague. *Pediatric Clinics of*
422 *North America* 1985, 32(4):953.
- 423 9. Webbe G: Human cysticercosis: parasitology, pathology, clinical manifestations
424 and available treatment. *Pharmacol Ther* 1994, 64(1):175-200.
- 425 10. Kuruvilla A, Pandian J, Nair M, Radhakrishnan V, Joseph S: Neurocysticercosis:
426 a clinical and radiological appraisal from Kerala State, South India. *Singapore*
427 *medical journal* 2001, 42(7):297-303.
- 428 11. Foyaca-Sibat H, Del Rio-Romero I: Prevalence Of Epilepsy In An Endemic Area
429 For Neurocysticercosis In South Africa. *The Internet Journal of Neurology* 2008,
430 9(1).
- 431 12. Pal DK, Carpio A, Sander JWAS: Neurocysticercosis and epilepsy in developing
432 countries. *Journal of Neurology, Neurosurgery & Psychiatry* 2000, 68(2):137-143.
- 433 13. Fleury A, Gomez T, Alvarez I, Meza D, Huerta M, Chavarria A, Carrillo Mezo R,
434 Lloyd C, Dessein A, Preux P: High prevalence of calcified silent
435 neurocysticercosis in a rural village of Mexico. *Neuroepidemiology* 2003,
436 22(2):139-145.
- 437 14. Devleeschauwer B, Aryal A, Joshi DD, Rijal S, Sherchand JB, Praet N,
438 Speybroeck N, Duchateau L, Vercruysse J, Dorny P: Epidemiology of *Taenia*
439 *solium* in Nepal: is it influenced by the social characteristics of the population and
440 the presence of *Taenia asiatica*? *Tropical Medicine & International Health* 2012.
- 441 15. Heap B: Cerebral cysticercosis as a common cause of epilepsy in Gurkhas in
442 Hong Kong. *Journal of the Royal Army Medical Corps* 1990, 136(3):146-149.
- 443 16. Bista M: Epidemiology, prevention and control of human cysticercosis/taeniasis
444 in Nepal. *Proceedings of present situation challenges in treatment and*
445 *elimination of Taeniasis/cysticercosis in Nepal, edited by Joshi DD, Sharma M,*
446 *Rana S National Zoonoses & Food Hygeine Research Centre, Kathmandu*
447 2006:12-14.
- 448 17. Joshi DD, Bista PR, Ito A, Yamasaki H: Present situation of porcine taeniasis and
449 human cysticercosis in Nepal. *South east Asian Journal of Tropical Medicine and*
450 *Public Health* 2007, 38:144.
- 451 18. Agrawal J: Neurocysticercosis in Nepal and It's Global Perspective. *Kathmandu*
452 *University Medical Journal* 2012, 9(2):1-2.
- 453 19. Basu S, Ramchandran U, Thapliyal A: Clinical profile and outcome of pediatric
454 neurocysticercosis: A study from Western Nepal. *Journal of Pediatric Neurology*
455 2007, 5(1):45-52.
- 456 20. Ellis M, Manandhar D, Manandhar N, Wyatt J, Bolam A, de LCostello A:
457 Stillbirths and neonatal encephalopathy in Kathmandu, Nepal: an estimate of the
458 contribution of birth asphyxia to perinatal mortality in a low-income urban
459 population. *Paediatric and perinatal epidemiology* 2000, 14(1):39-52.
- 460 21. Shrestha B: Childhood Neurocysticercosis: Clinico-Radiological Profile and
461 Outcome. *Journal of Nepal Paediatric Society* 2008, 28(1):14-16.
- 462 22. Garg RK, Malhotra HS: Solitary cysticercus granuloma. *Expert Review of Anti-*
463 *infective Therapy* 2012, 10(5):597-612.

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

- 464 23. Verma A, Prasad KN, Gupta RK, Singh AK, Nyati KK, Rizwan A, Pandey CM,
465 Paliwal VK: Toll-like receptor 4 polymorphism and its association with
466 symptomatic neurocysticercosis. *J. Infect. Dis.* 2010, 202(8):1219.
- 467 24. Del Brutto OH, Sotelo J, Román GC: *Neurocysticercosis*: Garland Science; 1998.
- 468 25. Wilson M, Bryan RT, Fried JA, Ware DA, Schantz PM, Pilcher JB, Tsang VCW:
469 Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot
470 in patients with neurocysticercosis. *J. Infect. Dis.* 1991, 164(5):1007-1009.
- 471 26. White AC: Neurocysticercosis: a major cause of neurological disease worldwide.
472 *Clin. Infect. Dis.* 1997, 24(2):101-113.
- 473 27. Dorny P, Brandt J, Zoli A, Geerts S: Immunodiagnostic tools for human and
474 porcine cysticercosis. *Acta Trop.* 2003, 87(1):79-86.
- 475 28. Sarti E, Schantz PM, Plancarte A, Wilson M, Gutierrez IO, Lopez AS, Roberts J,
476 Flisser A: Prevalence and risk factors for *Taenia solium* taeniasis and
477 cysticercosis in humans and pigs in a village in Morelos, Mexico. *The American*
478 *journal of tropical medicine and hygiene* 1992, 46(6):677-685.
- 479 29. Michelet L, Fleury A, Sciutto E, Kendjo E, Fragoso G, Paris L, Bouteille B:
480 Human neurocysticercosis: comparison of different diagnostic tests using
481 cerebrospinal fluid. *J. Clin. Microbiol.* 2011, 49(1):195-200.
- 482 30. Fleury A, Bouteille B, Garcia E, Marquez C, Preux P, Escobedo F, Sotelo J,
483 Dumas M: Neurocysticercosis: validity of ELISA after storage of whole blood
484 and cerebrospinal fluid on paper. *Tropical Medicine & International Health* 2001,
485 6(9):688-693.
- 486 31. Garcia H, Parkhouse R, Gilman R, Montenegro T, Bernal T, Martinez S,
487 Gonzalez A, Tsang V, Harrison L: Serum antigen detection in the diagnosis,
488 treatment, and follow-up of neurocysticercosis patients. *Trans. R. Soc. Trop. Med.*
489 *Hyg.* 2000, 94(6):673-676.
- 490 32. Carod J-F, Randrianarison M, Razafimahefa J, Ramahefarisoa RM,
491 Rakotondrazaka M, Debruyne M, Dautigny M, Cazal P, Andriantseho ML,
492 Charles ER: Evaluation of the performance of 5 commercialized enzyme
493 immunoassays for the detection of *Taenia solium* antibodies and for the diagnosis
494 of neurocysticercosis. *Diagnostic microbiology and infectious disease* 2012,
495 72(1):85-89.
- 496 33. Erhart A, Dorny P, Van De N, Vien HV, Thach DC, Toan ND, Cong LD, Geerts
497 S, Speybroeck N, Berkvens D: *Taenia solium* cysticercosis in a village in northern
498 Viet Nam: seroprevalence study using an ELISA for detecting circulating antigen.
499 *Trans. R. Soc. Trop. Med. Hyg.* 2002, 96(3):270-272.
- 500 34. Rodriguez S, Dorny P, Tsang VC, Pretell EJ, Brandt J, Lescano AG, Gonzalez
501 AE, Gilman RH: Detection of *Taenia solium* Antigens and Anti-*T. solium*
502 Antibodies in Paired Serum and Cerebrospinal Fluid Samples from Patients with
503 Intraparenchymal or Extraparenchymal Neurocysticercosis. *J. Inf. Dis.* 2009,
504 199(9):1345-1352.
- 505 35. Bobes RJ, Hernández M, Márquez C, Fragoso G, García E, Parkhouse RME,
506 Harrison LJ, Sciutto E, Fleury A: Subarachnoidal and intraventricular human

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

- neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. *Trop. Med. Int. Health* 2006, 11(6):943-950.
36. Diaz JF, Verastegui M, Gilman RH, Tsang V, Pilcher JB, Gallo C, Garcia HH, Torres P, Montenegro T, Miranda E: Immunodiagnosis of human cysticercosis (*Taenia solium*): a field comparison of an antibody-enzyme-linked immunosorbent assay (ELISA), an antigen-ELISA, and an enzyme-linked immunoelectrotransfer blot (EITB) assay in Peru. The Cysticercosis Working Group in Peru (CWG). *The American journal of tropical medicine and hygiene* 1992, 46(5):610.
37. Mandal J, Singhi P, Khandelwal N, Malla N: Evaluation of ELISA and dot blots for the serodiagnosis of neurocysticercosis, in children found to have single or multiple enhancing lesions in computerized tomographic scans of the brain. *Annals of tropical medicine and parasitology* 2006, 100(1):39-48.
38. Prasad A, Prasad KN, Yadav A, Gupta RK, Pradhan S, Jha S, Tripathi M, Husain M: Lymphocyte transformation test: a new method for diagnosis of neurocysticercosis. *Diag. Microbiol. Infect. Dis.* 2008, 61(2):198-202.
39. Garcia H, Herrera G, Diaz F, Verastegui M, Gallo C, Naranjo J, Miranda E, Martinez M, Porras M, Alvarado M: Diagnosis of cysticercosis in endemic regions. *The Lancet* 1991, 338(8766):549-551.
40. Tsang V, Wilson M: *Taenia solium* cysticercosis: An under-recognized but serious publica health problem. *Parasitol. Today* 1995, 11(3):124-126.
41. Hancock K, Khan A, Williams FB, Yushak ML, Pattabhi S, Noh J, Tsang VCW: Characterization of the 8-kilodalton antigens of *Taenia solium* metacestodes and evaluation of their use in an enzyme-linked immunosorbent assay for serodiagnosis. *J. Clin. Microbiol.* 2003, 41(6):2577-2586.
42. Tsang VCW, Peralta JM, Ray Simons A: [29] Enzyme-linked immunoelectrotransfer blot techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis. *Methods. Enzymol.* 1983, 92:377-391.
43. Wilson M, Bryan RT, Fried JA, Ware DA, Schantz PM, Pilcher JB, Tsang VC: Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. *J. Inf. Dis.* 1991, 164(5):1007-1009.
44. Garcia HH, Gilman RH, Catacora M, Verastegui M, Gonzalez AE, Tsang VCW: Serologic evolution of neurocysticercosis patients after antiparasitic therapy. *J. Infect. Dis.* 1997, 175(2):486.
45. Goodman KA, Ballagh SA, Carpio A: Case-control study of seropositivity for cysticercosis in Cuenca, Ecuador. *The American journal of tropical medicine and hygiene* 1999, 60(1):70-74.
46. García HH, Gilman RH, Tsang VCW, Gonzalez AE: Clinical significance of neurocysticercosis in endemic villages. *Trans. R Soc. Trop. Med. Hyg.* 1997, 91(2):176-178.

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

- 548 47. Schantz PM, Wilkins PP, Tsang VCW: Immigrants, imaging, and immunoblots:
549 the emergence of neurocysticercosis as a significant public health problem.
550 *Emerging infections* 1998;213-242.
- 551 48. Hauser WA, Hesdorffer DC: *Epilepsy: frequency, causes, and consequences*:
552 Epilepsy Foundation of America Landover, MD; 1990.
- 553 49. Rajshekhar V, Raghava MV, Prabhakaran V, Oommen A, Muliyl J: Active
554 epilepsy as an index of burden of neurocysticercosis in Vellore district, India.
555 *Neurology* 2006, 67(12):2135-2139.
- 556 50. Correa D, Sarti E, Tapia-Romero R, Rico R, Alcántara-Anguiano I, Salgado A,
557 Valdez L, Flisser A: Antigens and antibodies in sera from human cases of
558 epilepsy or taeniasis from an area of Mexico where *Taenia solium* cysticercosis is
559 endemic. *Ann. Trop. Med. Parasito.* 1999, 93(1):69-74.
- 560 51. Del Brutto O, Rajshekhar V, White Jr A, Tsang V, Nash T, Takayanagui O,
561 Schantz P, Evans C, Flisser A, Correa D: Proposed diagnostic criteria for
562 neurocysticercosis. *Neurology* 2001, 57(2):177-183.
- 563 52. Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL: Evidence-based
564 guideline: Treatment of parenchymal neurocysticercosis Report of the Guideline
565 Development Subcommittee of the American Academy of Neurology. *Neurology*
566 2013, 80(15):1424-1429.
- 567 53. Sotelo J, Jung H: Pharmacokinetic optimisation of the treatment of
568 neurocysticercosis. *Clin. pharm.* 1998, 34(6):503-515.
- 569 54. Takayanagui OM, Jardim E: Therapy for neurocysticercosis: comparison between
570 albendazole and praziquantel. *Archives of neurology* 1992, 49(3):290.
- 571 55. Carpio A, Santillan F, Leon P, Flores C, Hauser WA: Is the course of
572 neurocysticercosis modified by treatment with antihelminthic agents? *Archives of*
573 *internal medicine* 1995, 155(18):1982.
- 574 56. Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H, Hauser WA:
575 Effects of albendazole treatment on neurocysticercosis: a randomised controlled
576 trial. *Journal of Neurology, Neurosurgery & Psychiatry* 2008, 79(9):1050-1055.
- 577 57. Del Brutto OH: Medical management of neurocysticercosis. *Int. J. Ant. agents*
578 1993, 3(2):133-137.
- 579 58. DeGiorgio CM, Medina MT, Durón R, Zee C, Escueta SP: Neurocysticercosis.
580 *Epilepsy Curr.* 2004, 4(3):107-111.
- 581 59. Goel RK, Ahmad FU, Vellimana AK, Suri A, Chandra PS, Kumar R, Sharma BS,
582 Mahapatra AK: Endoscopic management of intraventricular neurocysticercosis. *J*
583 *Clin. Neuroscience* 2008, 15(10):1096-1101.
- 584 60. Suri A, Goel RK, Ahmad FU, Vellimana AK, Sharma BS, Mahapatra AK:
585 Transventricular, transaqueductal scope-in-scope endoscopic excision of fourth
586 ventricular neurocysticercosis: a series of 13 cases and a review. 2008.
- 587 61. Del Brutto OH: Prognostic factors for seizure recurrence after withdrawal of
588 antiepileptic drugs in patients with neurocysticercosis. *Neurology* 1994,
589 44(9):1706-1706.

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.

- 590 62. Budke CM, White AC, Garcia HH: Zoonotic larval cestode infections: neglected,
591 neglected tropical diseases? PLoS Neg. Trop. Dis 2009, 3(2):e319.
592 63. Evans CAW: 42 Taenia solium Vaccination: Present Status and Future Prospects.
593 *Taenia solium cysticercosis: from basic to clinical science* 2002:421.
594 64. Lightowers MW: Eradication of Taenia solium cysticercosis: a role for
595 vaccination of pigs. Int. J. Parasitol. 2010, 40(10):1183-1192.
596
597

Correspondence:

joshi.bishnu@gmail.com and neuronepal@wlink.com.np

Kathmandu, Nepal

Phone no:977-1-4256656 Po Box 24663.